Laura Farrington, DO
Medical Oncology · Zion, ILNPI 1073786745
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,910 of the $8,120 with a category attached, or 72.8%. It is spread thinly across 40 manufacturers, the largest accounting for just 22.4%. Reporting peaked in 2024 at $3,304 and has fallen 86.3% since, to $454 in 2025.
Across 346 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novartis$759
- Merck$630
- Gilead$561
- Pfizer$559
- E.r. Squibb & Sons, L.L.C.$411
- plus $3K from 34 others
Across 24 payments — averaging $9169.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$106K
- Merck$97K
- Novocure Inc.$16K
- Boehringer Ingelheim International GmbH$585
What the payments were for
- Consulting fees$1,57519%
- Speaking & faculty fees$2002%
- Food & beverage$5,91073%
- Education$4355%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $1,818 |
| Novartis | 48 | $759 |
| Merck | 35 | $630 |
| Gilead | 18 | $561 |
| Pfizer | 38 | $559 |
| E.r. Squibb & Sons, L.L.C. | 28 | $411 |
| Daiichi Sankyo Inc. | 7 | $336 |
| Johnson & Johnson(2 entities) | 26 | $309 |
| Lilly USA, LLC | 13 | $308 |
| Genentech USA, Inc. | 14 | $268 |
| Eisai Inc. | 8 | $188 |
| Astellas Pharma US Inc | 10 | $187 |
| Bayer | 9 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $170 |
| EMD Serono, Inc. | 12 | $150 |
| Seagen Inc. | 4 | $136 |
| Amgen | 6 | $131 |
| Springworks Therapeutics, Inc. | 4 | $121 |
| Aadi Bioscience, Inc. | 1 | $99 |
| Boehringer Ingelheim | 5 | $98 |
| Taiho Oncology, Inc. | 4 | $81 |
| Bristol Myers Squibb | 4 | $77 |
| GSK | 4 | $76 |
| Array Biopharma Inc | 4 | $61 |
| Deciphera Pharmaceuticals Inc. | 2 | $48 |
| Servier Pharmaceuticals LLC | 2 | $42 |
| Exelixis Inc. | 3 | $42 |
| Immunocore Limited | 1 | $35 |
| Ipsen Biopharmaceuticals, Inc | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Sanofi | 1 | $22 |
| Tesaro, Inc. | 1 | $22 |
| Coherus Oncology, Inc. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Medline Industries LP | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $14 |
| AbbVie | 1 | $12 |
| Fortovia Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,120 in reported general payments places this provider in the 75th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 11 | $171,836 |
| LynparzaOlaparib | 12 | $136,866 |
| ArimidexAnastrozole | 12 | $22,559 |
| EliquisApixaban | 11 | $8,506 |
| Anastrozole | 79 | $2,025 |
| Exemestane | 20 | $1,982 |
| Letrozole | 39 | $660 |
| Prochlorperazine Maleate | 27 | $516 |
| Ondansetron OdtOndansetron | 40 | $407 |
| Gabapentin | 42 | $349 |
| Levothyroxine Sodium | 47 | $311 |
| Dexamethasone | 27 | $295 |
| LoperamideLoperamide Hcl | 21 | $240 |
| Omeprazole | 15 | $92 |
| Tramadol Hcl | 19 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $559 | $180,34222 claims |
| AstraZenecaLynparza | $1,818 | $136,86612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 144 medical oncology providers in Illinois.
Other medical oncology in Zion
- Ryan EngelZion$19K
- Teja PoosarlaZion$4K
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Timothy KuzelOrland Park$265K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.